Skip to main
VYNE
VYNE logo

Vyne Therapeutics (VYNE) Stock Forecast & Price Target

Vyne Therapeutics (VYNE) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

VYNE Therapeutics is demonstrating promising clinical advancements, particularly with its VYN202 candidate, which has shown significant improvements in patient outcomes related to joint pain and inflammation, indicated by both quantitative data and visual evidence. The company is in a stable financial position, reporting approximately $40 million in cash reserves, enabling it to sustain operations and pursue strategic initiatives moving forward. Additionally, the potential of VYNE's pipeline—especially with FMX114 for atopic dermatitis and ongoing pre-clinical development of BET inhibitor compounds—bolsters a positive long-term outlook for the company's stock.

Bears say

VYNE Therapeutics Inc. has faced significant setbacks following its Phase 2b trial results for vitiligo, which missed primary endpoints, indicating a precarious position for the company. The trial revealed an unusually high vehicle effect and a concerning dropout rate in active treatment arms, leading to VYNE's decision to discontinue the treatment and terminate the trial altogether. Additionally, the company's previous optimistic outlook has shifted, as evidenced by the downgrade from a Buy rating to Neutral, reflecting declining confidence in its growth prospects and product viability.

Vyne Therapeutics (VYNE) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vyne Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vyne Therapeutics (VYNE) Forecast

Analysts have given Vyne Therapeutics (VYNE) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Vyne Therapeutics (VYNE) has a Strong Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vyne Therapeutics (VYNE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.